Millipore this week launched a set of AdenoSilence adenoviral shRNA expression vectors targeting the human druggable genome. Millipore said that the classes included in this release represent all of the major protein classes amenable to small-molecule intervention, including kinases, GPCRs, ion channels, proteases, nuclear hormone receptors, secreted proteins, and receptors.
The AdenoSilence vectors are available in three different sequence variants, and are sold individually or as a kit containing all three. The product is a result of a distribution agreement announced this year between Millipore and BioFocus, the drug-discovery service division of Galapagos.
DiscoverX this week said that it has expanded its cell-based PathHunter β-arrestin assays to include 45 validated cell products, each expressing a different Gi-, Gs-, or Gq-coupled receptor.
PathHunter β-arrestin assays are the first chemiluminescent GPCR assays that measure activation of Gi-, Gs-, or Gq-coupled receptor signaling by direct arrestin recruitment, as opposed to a second messenger, the company said.
Immunicon this week launched the EasyCount System, a fluorescent microscopy-based imaging system for counting dead and live nucleated cells, and calculating cell viability in a single test.
Immunicon said that researchers can perform as many as six tests at a time using the EasyCount Slide6 multi-well slide that is provided with the EasyCount ViaSure kit. The instrument can report total and live cell counts and calculate viability in less than one minute per test, Immunicon said.